IP Library › Granted Patent US 12,337,002
Granted Patent B2
US 12,337,002 · App. 18/057,031 · Granted Jun 24, 2025

Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives

Inventors: Mauro Ajani (Lainate, IT); Luigi Moro (Cairate, IT)
Assignee: CASSIOPEA S.P.A.
A61K31/573A61K9/0014A61K9/06A61K47/06A61K47/10A61K47/14A61K47/26A61K47/44C07J5/0053C07J7/008C07B2200/13C12P33/005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,337,002
App. No.
18/057,031
Granted
Jun 24, 2025
Kind
B2
Abstract

The present invention refers to a new enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17α-propionate and 9,11-dehydro-cortexolone 17α-butanoate.

Claims (30)

1. A pharmaceutical composition comprising cortexolone 17α-propionate in at least one of polymorphic forms I, III, or IV, propylene glycol, cetyl alcohol, glyceryl monostearate, liquid paraffin, tocopherol, polyoxyethylene (80) sorbitan monooleate, and water, wherein:

a) polymorphic form I is characterized by a DRX with at least peaks at about: 7.6, 8.4, 17.0, and 20.1 degrees 2theta;

b) polymorphic form III is characterized by a DRX with at least peaks at about: 6.2, 12.6, 22.4, and 23.7 degrees 2theta; and

c) polymorphic form IV is characterized by DRX with at least peaks at about: 4.8, 12.9, and 19.5 degrees 2theta.

2. The pharmaceutical composition of claim 1 , wherein the cortexolone 17α-propionate comprises solvate crystalline form IV of cortexolone 17α-propionate.

3. The pharmaceutical composition of claim 1 , wherein the cortexolone 17α-propionate comprises cortexolone 17α-propionate of crystalline form III.

4. The pharmaceutical composition of claim 2 , wherein the cortexolone 17α-propionate further comprises cortexolone 17α-propionate of crystalline form III.

5. The pharmaceutical composition of claim 1 , wherein the cortexolone 17α-propionate is present in the composition in an amount of 0.1 to 2 wt %.

6. The pharmaceutical composition of claim 2 , wherein the cortexolone 17α-propionate is present in the composition in an amount of 0.1 to 2 wt %.

7. The pharmaceutical composition of claim 1 , wherein the cortexolone 17α-propionate is present in the composition in an amount of 0.2 to 1 wt %.

8. The pharmaceutical composition of claim 2 , wherein the cortexolone 17α-propionate is present in the composition in an amount of 0.2 to 1 wt %.

9. The pharmaceutical composition of claim 1 , wherein the cortexolone 17α-propionate is present in the composition in an amount of about 1 wt %.

10. The pharmaceutical composition of claim 2 , wherein the cortexolone 17α-propionate is present in the composition in an amount of about 1 wt %.

11. The pharmaceutical composition of claim 1 , wherein the tocopherol is mixed tocopherols.

12. The pharmaceutical composition of claim 1 , wherein the composition is formulated for topical administration.

13. The pharmaceutical composition of claim 2 , wherein the composition is formulated for topical administration.

14. The pharmaceutical composition of claim 1 , wherein the composition is an emulsion.

15. The pharmaceutical composition of claim 2 , wherein the composition is an emulsion.

16. The pharmaceutical composition of claim 1 , wherein the composition is a cream.

17. The pharmaceutical composition of claim 2 , wherein the composition is a cream.

18. The pharmaceutical composition of claim 14 , wherein the composition is a cream.

19. The pharmaceutical composition of claim 1 , wherein the composition comprises:

about 1 wt % cortexolone 17α-propionate,

about 24.7 wt % propylene glycol,

about 2.5 wt % cetyl alcohol,

about 14.8 wt % glyceryl monostearate,

about 9.9 wt % liquid paraffin,

about 1 wt % polyoxyethylene (80) sorbitan monooleate.

20. The pharmaceutical composition of claim 19 further comprising about 0.05 wt % tocopherol.

21. A method of treating acne in a subject in need thereof, the method comprising topically administering an effective amount of the pharmaceutical composition of claim 1 to an affected area on the subject.

Assignments (4)
CHANGE OF ADDRESS Recorded Jun 27, 2025
From: CASSIOPEA S.P.A.
To: CASSIOPEA S.P.A.
Reel/Frame 071752/0186 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2023
From: AJANI, MAURO; MORO, LUIGI
To: COSMO S.P.A.
Reel/Frame 065512/0906 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2023
From: COSMO S.P.A.
To: COSMO DERMATOS SRL
Reel/Frame 065512/0944 →
CHANGE OF NAME Recorded Nov 9, 2023
From: COSMO DERMATOS SRL
To: CASSIOPEA S.P.A.
Reel/Frame 065532/0748 →
Priority Claims (1)
IT MI2007A001616 · Aug 3, 2007 · national
Continuity (7)
Continuation 17455538 · Nov 18, 2021
Continuation 16686738 · Nov 18, 2019
Continuation 16195083 · Nov 19, 2018
Continuation 15211087 · Jul 15, 2016
Division 14073928 · Nov 7, 2013
Division 12671932
Related Publication 20230104965A1 · Apr 6, 2023
References Cited (97)
US 2985650A · Batres et al. · 1961 [cited by applicant]
US 3152154A · Ercoli et al. · 1964 [cited by applicant]
US 3431173A · Van Der Waard et al. · 1969 [cited by applicant]
US 3530038A · De Flines et al. · 1970 [cited by applicant]
US 3733318A · Marx · 1973 [cited by applicant]
US 3780177A · Ercoli et al. · 1973 [cited by applicant]
US 4290962A · Tachi et al. · 1981 [cited by applicant]
US 4318853A · Ayer et al. · 1982 [cited by applicant]
US 4645763A · Annen et al. · 1987 [cited by applicant]
US 4670427A · Annen et al. · 1987 [cited by applicant]
US 5264428A · Streber et al. · 1993 [cited by applicant]
US 8785427B2 · Ajani et al. · 2014 [cited by applicant]
US 9433628B2 · Ajani et al. · 2016 [cited by applicant]
US 9486458B2 · Ajani et al. · 2016 [cited by applicant]
US 10159682B2 · Ajani et al. · 2018 [cited by applicant]
US 10166245B2 · Ajani et al. · 2019 [cited by applicant]
US 20040138187A1 · Reading et al. · 2004 [cited by applicant]
US 20050026889A1 · Ajani et al. · 2005 [cited by applicant]
US 20050227994A1 · Gemba et al. · 2005 [cited by applicant]
US 20110092472A1 · Ajani et al. · 2011 [cited by applicant]
US 20120149671A1 · Ajani et al. · 2012 [cited by applicant]
US 20140079686A1 · Barman et al. · 2014 [cited by applicant]
US 20140154306A1 · Ajani et al. · 2014 [cited by applicant]
US 20140179654A1 · Ajani et al. · 2014 [cited by applicant]
US 20160051566A1 · Ajani et al. · 2016 [cited by applicant]
US 20160324873A1 · Ajani et al. · 2016 [cited by applicant]
US 20190282589A1 · Longo · 2019 [cited by applicant]
US 20190374553A1 · Longo · 2019 [cited by applicant]
AU 729928B2 · 2001 [cited by applicant]
DE 19653730A1 · 1998 [cited by applicant]
EP 1421099A1 · 2004 [cited by applicant]
GB 791771A · 1958 [cited by applicant]
IT MI20132157A1 · 2015 [cited by applicant]
JP 52010489 · 1977 [cited by applicant]
JP 59106500A · 1984 [cited by applicant]
JP 60161998A · 1985 [cited by applicant]
JP 2004530703A · 2004 [cited by applicant]
JP 2005504762A · 2005 [cited by applicant]
JP 2005539016A · 2005 [cited by applicant]
WO WO8809337A1 · 1988 [cited by applicant]
WO WO02094843A1 · 2002 [cited by applicant]
WO WO03014141A1 · 2003 [cited by applicant]
WO WO03080042A1 · 2003 [cited by applicant]
WO WO2004014935A1 · 2004 [cited by applicant]
WO WO2004060347A2 · 2004 [cited by applicant]
WO WO2005004917A2 · 2005 [cited by applicant]
WO WO2006121097A1 · 2006 [cited by applicant]
WO WO2007014927A2 · 2007 [cited by applicant]
WO WO2007031349A1 · 2007 [cited by applicant]
Annen, K., et al., “17-Pivalate in der Pregnanreihe,” Liebigs Ann Chem 705-711, Wiley-VCH Verlag GmbH & Co. KGaA, Germany (1983). [cited by applicant]
Baldessari et al., “86. Lipase-Catalysed Regioselective Deacetylation of Androstane Derivatives,” Helvetica Chimica Acta 79 (1996). [cited by applicant]
Belieu, R.M., “Mastodynia,” Obstet Gynecol Clin North Am 21(3):461-477, W.B. Saunders Company, United States (Sep. 1994). [cited by applicant]
Biollaz, von M. and Kalvoda, J., “263. Reaktionen von Steroiden mit Dialkylaminoschwefeltrifluoriden. I. 11β-Hydroxysteroide.” Helvetica Chimica Acta 60(8):2703-2710, Schweizerische Chemische Gesellschaft, Switzerland (… [cited by applicant]
Bruttomesso, et al., “Lipase-catalysed deacetylation of androstane and pregnane deriratives: influence of ring D substitution,” Journal of Melecular Catalysis B: Ensymatic 29:149-153 (2004). [cited by applicant]
Caira, M.R., “Crystalline Polymorphism of Organic Compounds,” in Topics in Current Chemistry, vol. 198, de Meijere, A., et al., Eds., pp. 164-208, Springer-Verlag, Germany (1998). [cited by applicant]
Celasco, G., et al., “Biological Profile of Cortexolone 17μ-Propionate (CB-03-01), a New Topical and Peripherally Selective Androgen Antagonist,” Arzneimittelforschung 54(12):881-886, Thieme Medical Publishers, Germany … [cited by applicant]
Cheung, et al., “Resistance to enzymic hydrolysis as a parameter in drug potency,” International Journal of Pharmaceuticals 27:325-333 (1985). [cited by applicant]
Ferraboschi, et al., “Lipase-catalyzed preparation of corticosteroid 17u-esters endowed with antiandrogenic activity,” Tetrahedron Letters 49:4610-4612 (2008). [cited by applicant]
Ford, J.L. and Timmins, P., Eds., “Ch. 6 Thermal analysis in the characterization of pharmaceutical solids,” in Pharmaceutical Thermal Analysis: Techniques and Applications, pp. 139-140, Ellis Horwood Limited, England (… [cited by applicant]
Franssen, et al., “Enzymatic alcoholysis of alkoxymethyl alkanoates: a possibile approach for the kinetic resolution of tertiary alcohols,” Tetrahedron Letters 39:8345-8348 (2004). [cited by applicant]
Gardi, R., et al., “52. Derivati di condensazione nella catena laterale di corticosteroidi.—Nota III. Preparazione e reazioni dei 17-monesteri,” Gazz. Chim. It. 93:431-450, Palermo, Italy (1963). [cited by applicant]
Gardi, R., et al., “Corticosteroid 17α-Monoesters from 17α,21-Cyclic Orthoesters,” Tetrahedron Letters 13:448-451, Pergamon Press Ltd., United Kingdom (1961). [cited by applicant]
Hilfiker, R., Ed., “Characterization of Polymorphic Systems Using Thermal Analysis,” in Polymorphisms in the Pharmaceutical Industry, pp. 46-48, Wiley-VCH Verlag GmbH & Co. KGaA, Germany (2006). [cited by applicant]
Meriggiola, M.C. and Pelusi, G., “Advances in male hormonal contraception,” Expert Opin Investig Drugs 15(4):389-397, Ashley Publications, United Kingdom (Apr. 2006). [cited by applicant]
Misaki, et al., “Enzymic hydrolysis of hydrocoristone diesters in skin,” Yakuzaigaku No. 42(2), Abstract. Caplus Chemical Abstract Service Database Accession No., 1982:575431. [cited by applicant]
Morrison, R.T. and Boyd, R.N., Eds., “Chap. 20 Functional Derivatives of Carboxylic Acids,” in Organic Chemistry, Sixth Edition, pp. 764-766, Prentice-Hall, Inc., Englewood Cliffs, New Jersey, United States (1992). [cited by applicant]
Schinzer, W.C., et al., “Characterization and Interconversion of Polymorphs of Premafloxacin, a New Quinolone Antibiotic,” J Pharm Sci 86(12):1426-1431, American Chemical Society and American Pharmaceutical Association,… [cited by applicant]
Tuladhar, M.D., et al., “Thermal behaviour and dissolution properties of phenylbutazone polymorphs,” J Pharm Pharmacol 35(4):208-214, Oxford University Press, United Kingdom (Apr. 1983). [cited by applicant]
Turner, R.B., “Acylation of 17-Hydroxy-20-ketosteroids,” J. Am. Chem. Soc. 75:3489-3492, American Chemical Society, United States (1953). [cited by applicant]
Voigt, W. and Hsia, S.L., “The Antiandrogenic Action of 4-Androsten-3-one-17β-Carboxylic Acid and Its Methyl Ester on Hamster Flank Organ,” Endocrinology 92(4):1216-1222, Endocrine Society, United States (Apr. 1973). [cited by applicant]
Japanese Office Action for Application No. 2010-518628 dated Feb. 8, 2013. [cited by applicant]
Non-Final Office Action, mailed Sep. 25, 2006 for U.S. Appl. No. 10/486,386, filed Sep. 16, 2004. [cited by applicant]
Final Office Action, mailed Apr. 13, 2007 for U.S. Appl. No. 10/486,386, filed Sep. 16, 2004. [cited by applicant]
Non-Final Office Action, mailed Sep. 7, 2007 for U.S. Appl. No. 10/486,386, filed Sep. 16, 2004. [cited by applicant]
Final Office Action, mailed Mar. 21, 2008 for U.S. Appl. No. 10/486,386, filed Sep. 16, 2004. [cited by applicant]
Non-Final Office Action, mailed Jul. 10, 2008 for U.S. Appl. No. 10/486,386, filed Sep. 16, 2004. [cited by applicant]
Final Office Action, mailed Feb. 27, 2009 for U.S. Appl. No. 10/486,386, filed Sep. 16, 2004. [cited by applicant]
Non-Final Office Action, mailed Jul. 13, 2011 for U.S. Appl. No. 12/457,870, filed Jun. 24, 2009. [cited by applicant]
Non-Final Office Action, mailed Apr. 24, 2014 for U.S. Appl. No. 14/103,707, filed Dec. 11, 2013. [cited by applicant]
Byrn, S., et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharm Res 12(7):945-954, Plenum Publishing Company, United States (Jul. 1995). [cited by applicant]
Notice of Allowance, mailed Sep. 23, 2015 for U.S. Appl. No. 14/474,765, Ajani, M., et al., filed Sep. 2, 2014. [cited by applicant]
Bavin, M., “Polymorphism in process development. (crystal structure transformations)” in Chemistry and Industry, accessed at https://www.highbeam.com/doc/1G1-7901419.html, accessed on Nov. 17, 2016, Society of Chemical … [cited by applicant]
Office Action mailed Nov. 28, 2017, in U.S. Appl. No. 15/211,087, inventor Ajani, M. et al., filed Jul. 15, 2016, 6 pages. [cited by applicant]
Office Action mailed May 10, 2018, in U.S. Appl. No. 15/211,087, inventor Ajani, M. et al., filed Jul. 15, 2016, 8 pages. [cited by applicant]
Office Action mailed Nov. 20, 2017, in U.S. Appl. No. 15/211,094, inventor Ajani, M. et al., filed Jul. 15, 2016, 6 pages. [cited by applicant]
Office Action mailed May 3, 2018, in U.S. Appl. No. 15/211,094, inventor Ajani, M. et al., filed Jul. 15, 2016, 7 pages. [cited by applicant]
Clinical trials data published on Oct. 31, 2014, retrieved from https://clinicaltrials.gov/ct2/history/NCT02279823?V_1=View#studypagetop, 7 pages. [cited by applicant]
Cosmo Pharmaceuticals S.p.A. Reports Exciting Results in P.O.C. Alopecia Study, published on Oct. 6, 2010, retrieved from https://www.biospace.com/article/releases/cosmo-pharmaceuticals-s-p-a-reports-exciting-results-in… [cited by applicant]
Blagden, N., et al., “Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates,” Advanced Drug Delivery Reviews 59:617-630, Elsevier B.V., Netherlands (2007). [cited by applicant]
Morissette, S. L., et al., “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids,” Advanced Drug Delivery Reviews 56:275-300, Elsevier B.V., Netherlands (2004). [cited by applicant]
Vishweshwar, P., et al., “Pharmaceutical Co-Crystals,” Journal of Pharmaceutical Sciences 95(3):499-516, Wiley-Liss, Inc. and the American Pharmacists Association, United States (2006). [cited by applicant]
Khankari, R. K., et al., “Pharmaceutical hydrates,” [cited by applicant]
Piacquadio, D., et al., “Safety and steady state pharmacokinetics of cortexolone 17a-propionate (cb-03-01) 1% cream in adult subjects with acne vulgaris,” [cited by applicant]
Non-Final Office Action mailed Jul. 25, 2019 for U.S. Appl. No. 16/400,262, filed May 1, 2019. [cited by applicant]
Third Party Submission dated Oct. 17, 2019, mailed Oct. 22, 2019 for U.S. Appl. No. 16/400,262, filed May 1, 2019 (21 pages). [cited by applicant]
Non-Final Office Action mailed Oct. 2, 2019 for U.S. Appl. No. 16/195,083, filed Nov. 19, 2018. [cited by applicant]
Final Office Action mailed Mar. 17, 2020 for U.S. Appl. No. 16/195,083, filed Nov. 19, 2018. [cited by applicant]